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Abstract 
Purpose: Previous studies assessing impact of acute respiratory distress syndrome (ARDS) on mortality have shown 
conflicting results. We sought to assess the independent association of ARDS with in-hospital mortality among inten-
sive care unit (ICU) patients with sepsis.
Methods: We studied two prospective sepsis cohorts drawn from the Early Assessment of Renal and Lung Injury 
(EARLI; n = 474) and Validating Acute Lung Injury markers for Diagnosis (VALID; n = 337) cohorts. ARDS was defined 
by Berlin criteria. We used logistic regression to compare in-hospital mortality in patients with and without ARDS, 
controlling for baseline severity of illness. We also estimated attributable mortality, adjusted for illness severity by 
stratification.
Results: ARDS occurred in 195 EARLI patients (41%) and 99 VALID patients (29%). ARDS was independently associ-
ated with risk of hospital death in multivariate analysis, even after controlling for severity of illness, as measured 
by APACHE II (odds ratio [OR] 1.65 (95% confidence interval [CI] 1.02, 2.67), p = 0.04 in EARLI; OR 2.12 (CI 1.16, 3.92), 
p = 0.02 in VALID). Patients with severe ARDS (P/F < 100) primarily drove this relationship. The attributable mortality of 
ARDS was 27% (CI 14%, 37%) in EARLI and 37% (CI 10%, 51%) in VALID. ARDS was independently associated with ICU 
mortality, hospital length of stay (LOS), ICU LOS, and ventilator-free days.
Conclusions: Development of ARDS among ICU patients with sepsis confers increased risk of ICU and in-hospital 
mortality in addition to other important outcomes. Clinical trials targeting patients with severe ARDS will be best 
poised to detect measurable differences in these outcomes.
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Introduction
Acute respiratory distress syndrome (ARDS) is a clinical 
syndrome in critically ill patients involving acute respira-
tory failure, hypoxemia, and non-cardiogenic pulmonary 
edema [1, 2]. To date, there are no effective pharmaco-
therapies for ARDS. The attributable mortality for ARDS 
among patients with sepsis, the most common ARDS risk 
factor, has not been previously estimated. Empiric esti-
mation of the effect of ARDS on mortality is crucial in 
this population for the design of future clinical trials.
Proximal causes of death are notoriously difficult to 
identify in critically ill patients, particularly since most 
ICU patients die after withdrawal of life-sustaining meas-
ures [3, 4]. Given that the supportive therapies shown to 
reduce mortality in ARDS include primarily a ventilator 
strategy and prone positioning, it may seem implicit that 
there exists some modifiable mortality attributable to 
ARDS related to oxygenation [5, 6]. However, for decades, 
it has been clear that refractory hypoxemia accounts for 
only a small fraction of deaths in ARDS [7, 8]. A recent 
study showed the majority of deaths of ICU patients 
with ARDS were not directly related to lung damage [9]. 
Thus, it has been challenging to determine what pro-
portion of mortality is attributable to ARDS itself (and 
therefore a potential target for ARDS-focused clinical 
trials), and what proportion is driven by the underlying 
ARDS risk factor, comorbidities, or a combination of the 
two. Quantifying the ARDS-attributable mortality—the 
excess mortality among patients with ARDS that can be 
attributed to ARDS—would help inform design of future 
ARDS clinical trials.
Previous studies examining the impact of ARDS on 
mortality have shown conflicting results [10–17]. In 
a large retrospective study of ventilated ICU patients, 
development of early or late ARDS was not associated 
with an increase in mortality at 28  days [17]. However, 
severe ARDS was associated with increased mortality 
at 2 years. These studies have varied tremendously with 
regard to patient population and controlling for base-
line severity of illness. Notably, many studies focused on 
trauma populations, a subgroup which may not be rep-
resentative of patients with other ARDS risk factors [18]. 
The relevance of older studies to current practice is also 
unclear, given most were performed before the era of low 
tidal volume ventilation and modern resuscitation prac-
tices. Recent studies have not focused on sepsis, the most 
common ARDS risk factor.
Using two prospective ICU cohorts, we assessed 
whether development of ARDS in the current era is inde-
pendently associated with mortality among medical and 
surgical ICU patients with sepsis. Limited results from 
this study were reported in abstract [19].
Methods
Participants
We studied patients from two prospectively enrolled crit-
ically ill adult cohorts: (1) Early Assessment of Renal and 
Lung Injury (EARLI) study and (2) Validating Acute Lung 
Injury markers for Diagnosis (VALID) study [20–23]. The 
EARLI cohort includes adult patients admitted from the 
emergency department to an ICU at either an academic 
medical center or county hospital in San Francisco, Cali-
fornia [20, 22]. The VALID cohort includes adult patients 
from an academic medical center in Nashville, Tennessee 
[21, 23]. EARLI was approved by the University of Cali-
fornia, San Francisco Institutional Review Board (IRB). 
VALID was approved by the Vanderbilt IRB. In both 
cohorts, consent was obtained from patients or their sur-
rogates when possible. Further details about enrollment 
and consent have been reported and are provided in the 
online data supplement [20–23].
Primary outcome and additional variables
We selected patients with sepsis from the EARLI and 
VALID cohorts. Sepsis was defined as documented 
or suspected infection in the presence of two or more 
characteristics of the systemic inflammatory response 
syndrome [24]. Enrollment and data collection for both 
cohorts began before the advent of Sepsis 3, and our 
coding for sepsis reflects the prior definition. Patients 
were defined as having ARDS if they met Berlin criteria 
for ARDS on at least 1  day between hospital days one 
through five in EARLI and between hospital days one 
through four in VALID [1]. We additionally identified 
patients who met the American-European Consensus 
Conference (AECC) criteria for acute lung injury (ALI) 
during the same time frame [25]. Shock was defined as 
use of vasopressors within the first 48 h of ICU stay. Code 
status at admission was assessed in EARLI based on doc-
umented preferences in medical records.
Severity of illness was assessed using APACHE II and 
SAPS II in both cohorts. In EARLI, APACHE III was also 
assessed. Modified APACHE scores that exclude points 
related to oxygenation were generated [10]. The primary 
outcome in both cohorts was in-hospital mortality. Sec-
ondary outcomes included ICU mortality, hospital length 
of stay (LOS), ICU LOS, and ventilator-free days (VFDs). 
Take‑home message 
In two prospective cohorts of critically ill patients with sepsis, 
development of ARDS conferred increased risk for hospital mortality, 
independent of overall severity of illness. This association was driven 
almost entirely by those patients with severe ARDS. Development of 
ARDS was also associated with increased intensive care (ICU) mortal-
ity, hospital length-of-stay, and ICU length-of-stay.
P/F ratios were used to stratify patients by severity of 
ARDS. Additional detail is provided in the online data 
supplement.
Statistical methods
Student’s t tests, Pearson’s Chi-square test, and Mann–
Whitney–Wilcoxon tests were used to compare base-
line variables between cohorts as well as within cohorts 
stratified by development of ARDS and mortality. We 
generated a directed acyclic graph (DAG) to illustrate the 
relationship between ARDS and death and to categorize 
variables as potential confounders or effect mediators 
(Supplementary Figure S1) [26]. Multivariate logistic, lin-
ear, and zero-inflated negative binomial regression mod-
els were developed for primary and secondary outcomes 
as described in detail in the online data supplement.
Sensitivity analyses were performed in EARLI by 
restricting analyses to patients with pulmonary sepsis 
and shock and patients without limitations in code sta-
tus, and by excluding patients who died within the first 
5  days of hospitalization and therefore may have died 
before development of ARDS was possible. We also per-
formed a sensitivity analysis of hospital and ICU LOS in 
which we included all participants (not just survivors). 
In both cohorts, patients, who met the AECC criteria for 
ALI but were not mechanically ventilated, were excluded 
from the primary analysis [25]. Sensitivity analyses were 
also performed by including these patients as cases.
In both cohorts, we determined the attributable frac-
tion of mortality from ARDS  (AFARDS) and the population 
attributable fraction of mortality from ARDS (population 
 AFARDS) using methods outlined previously (additional 
detail in the online supplement) [27–29]. The  AFARDS is 
the proportion of deaths attributable to ARDS among all 
deaths in patients who developed ARDS. The population 
 AFARDS is the proportion of deaths attributable to ARDS 
among all deaths in the population of patients with sep-
sis. Estimates were based on indirect standardization, 
which computes the weighted average of stratum-specific 
estimates in the reference population, using weights from 
the study population. Strata were defined by modified 
APACHE II quartiles. An additional sensitivity analy-
sis was performed among pooled data from EARLI and 
VALID to assess for a data-driven P/F cutoff for severe 
ARDS that best captures mortality. A two-sided P value 
less than 0.05 was considered statistically significant. 
Analyses were performed using STATA 15 software (Col-
lege Station, TX) and Proc STDRATE in SAS (v9.4).
Results
Baseline characteristics and clinical outcomes
Patient selection is presented in Fig. 1. Table 1 presents 
baseline characteristics from each cohort. The EARLI 
population was generally older and more racially diverse 
compared to the VALID population. Most patients in 
both cohorts were cared for by a medical ICU service 
(compared to surgical service). While patients in each 
cohort had similar modified APACHE II scores, the 
EARLI cohort had higher SAPS II scores. While the pro-
portion of patients requiring mechanical ventilation was 
similar, significantly more patients developed ARDS in 
EARLI compared to VALID. EARLI patients were more 
likely to meet severe ARDS criteria compared to VALID. 
Hospital LOS was longer in VALID. ICU and in-hospital 
mortality were higher in EARLI.
Table  1 also shows each cohort stratified by develop-
ment of ARDS. In both cohorts, patients who developed 
ARDS were more likely to have sepsis from a pulmonary 
source, had higher baseline severity of illness scores, and 
were more likely to require vasopressor use in the first 
48 h than patients who did not develop ARDS. Patients 
in both cohorts with ARDS had greater hospital and ICU 
mortality, longer LOS, and fewer VFDs. Limited data on 
mechanical ventilation of ARDS patients are presented in 
Supplemental Table 2.
Comparison of clinical outcomes adjusted for severity 
of illness
EARLI
Of 474 patients, 137 (29%) died prior to hospital dis-
charge (Table  2A). Patients who died were older and 
more likely to have a limit on code status at the time of 
admission when compared to patients who survived. 
Patients who died were also more severely ill, with higher 
modified APACHE II and III scores, higher SAPS II 
scores, increased vasopressor use in the first 48  h, and 
more likely to develop ARDS than survivors. Among 
those who died, 61% developed ARDS during hospitali-
zation compared with 33% among survivors (p < 0.001).
The unadjusted in-hospital mortality rate was 43% for 
patients with ARDS compared to 19% without (Table 3; 
OR = 3.09; 95% CI 2.05, 4.66; p < 0.001). In creating 
adjusted models, no variables in addition to those pre-
specified (modified APACHE score, age, limitation on 
code status at admission, and being admitted from a 
nursing home) met criteria for inclusion in the model as 
outlined in the methods. In logistic regression adjusted 
for modified APACHE II, age, limitation on code status, 
and admission from nursing home, the OR for hospital 
death among patients with ARDS in EARLI was attenu-
ated by adjustment, but remained statistically signifi-
cant. In addition, ARDS was associated with increased 
risk of ICU death in all unadjusted and adjusted models 
(Table 3A). Results were similarly unchanged when anal-
yses were expanded to the AECC ALI criteria that did not 
require mechanical ventilation (Supplementary Table S3). 
The other sensitivity analyses (excluding patients admit-
ted from a nursing home or having a limitation on code 
status at admission and excluding patients who died 
within the first 5  days of hospitalization) did not sig-
nificantly alter the results (data not shown). Relative to 
patients with sepsis who did not develop ARDS, patients 
who developed ARDS had a longer hospital and ICU LOS 
in both adjusted and unadjusted models, whether limited 
to only survivors or among all patients (online data sup-
plement Table S4 and S5).
In EARLI, we additionally adjusted for modified 
APACHE III or unmodified SAPS II in place of modified 
APACHE II. The association between ARDS and in-hos-
pital mortality was no longer statistically significant when 
including a modified APACHE III or SAPS II, though 
the ORs remained similar. For ICU mortality, hospital 
LOS, and ICU LOS, results were largely unchanged when 
adjusting for the alternative severity of illness measures 
(Table 3, Supplementary Tables S3 and S4).
We also performed analyses stratifying by severity of 
ARDS using the Berlin criteria (1). Severe ARDS con-
ferred independent risk of both hospital and ICU mor-
tality in both unadjusted and adjusted models (Fig.  2, 
Supplementary Table  S6). In adjusted models, severe 
ARDS was associated with hospital and ICU mortality 
with ORs of 2.42 (95% CI 1.24, 4.72; p = 0.01) and 3.08 
(95% CI 1.53, 6.21; p = 0.002), respectively. In contrast, 
mild and moderate ARDS were not independently associ-
ated with mortality. In EARLI, the  AFARDS was 27% (CI, 
14–37%) and the population  AFARDS was 16% (95% CI, 
5–27%).
VALID
Of 337 patients, 60 (18%) died prior to hospital discharge 
(Table  2B). Patients who died were more likely to be 
white. They also had higher modified APACHE II scores, 
SAPS II scores, and increased vasopressor use and were 
more likely to develop ARDS than survivors. Among 
those who died, 48% developed ARDS during hospitali-
zation compared with 25% among survivors (p < 0.001).
The unadjusted in-hospital mortality rate was 28% for 
patients with ARDS compared to 13% for patients with-
out (OR = 2.77; 95% CI 1.56, 4.91; p = 0.001) (Table 3B). 
Similar to findings in EARLI, in multivariate logistic 
regression, development of ARDS in the overall VALID 
sample was an independent risk factor for both hospi-
tal and ICU death. Results were similar in models using 
SAPS II as a marker for severity of illness. Again, results 
were largely unchanged when analyses were expanded 
to include the AECC ALI criteria that did not require 
mechanical ventilation (Supplementary Table  S3) or 
Fig. 1 Study flowcharts for the EARLI and VALID cohorts
excluding patients who died within the first 5 days (data 
not shown).
As in EARLI, development of ARDS conferred 
increased risk of prolonged hospital and ICU LOS as 
well as fewer VFDs (Supplementary Tables S3 and S4). 
In addition, the association between ARDS and mor-
tality was also stratified by severity of ARDS using 
the Berlin criteria (1). In VALID, severe ARDS again 
conferred independent risk of in-hospital mortality in 
unadjusted and adjusted models (Fig.  2, Supplemen-
tary Table S6). The OR for hospital and ICU mortality 
adjusted for APACHE II was 2.12 (95% CI 1.16, 3.92; 
p = 0.02) and 2.67 (95% CI 1.35, 5.27; p = 0.01), respec-
tively. The analysis of in-hospital mortality did not 
reach statistical significance in the model adjusted for 
SAPS II, though ORs were similar to other models and 
those in EARLI (online data Supplementary Table S5). 
In VALID, the  AFARDS was 37% (10–51%) and the pop-
ulation  AFARDS was 18% (95% CI, 0.3%, 32%).
In a sensitivity analysis performed on pooled data 
from EARLI and VALID to determine a data-driven 
threshold for capturing mortality of severe ARDS, the 
risk of mortality appeared to plateau at a P/F ratio of 
120 (Supplementary Figure S3).
Table 1 Baseline characteristics of EARLI and VALID cohorts, together and stratified by ARDS
Table excludes all patients who met the AECC definition of acute lung injury but were not intubated
LOS length of stay
*Data shown as mean ± standard deviation, number (percent), or median (interquartile range) as appropriate
† Modified APACHE scores exclude points related to oxygenation
‡ Restricted to survivors
Clinical variable* All patients EARLI (n = 474) VALID (n = 337)
EARLI (n = 474) VALID (n = 337) No ARDS
(n = 279)
ARDS
(n = 195)
p value No ARDS (n = 238) ARDS (n = 99) p value
Age, years 66 ± 17 56 ± 16 65 ± 17 68 ± 16 0.07 56 ± 15 53 ± 17 0.11
Male gender, % 255 (54) 169 (50) 153 (55) 102 (52) 0.59 117 (49) 52 (53) 0.57
White race, % 239 (50) 267 (79) 139 (50) 100 (51) 0.75 182 (76) 85 (86) 0.05
Any limitation on code status at 
admission, %
88 (19) – 52 (19) 36 (18) 0.96 – – –
Admitted from nursing facility, % 96 (20) – 54 (19) 42 (22) 0.56 – – –
Pulmonary sepsis, % 277 (58) 172 (51) 125 (45) 152 (78) < 0.001 98 (41) 74 (75) < 0.001
Primary Service Medicine, % 429 (91) 319 (95) 246 (88) 183 (94) 0.07 228 (96) 91 (92) 0.15
APACHE II score 27 ± 9 27 ± 9 24 ± 8 31 ± 10 < 0.001 25 ± 9 30 ± 8 < 0.001
Modified APACHE II  score† 25 ± 9 25 ± 8 23 ± 7 29 ± 9 < 0.001 24 ± 8 28 ± 8 < 0.001
APACHE III score 95 ± 39 – 83 ± 33 113 ± 40 < 0.001 – – –
Modified APACHE III  score† 90 ± 36 – 80 ± 31 104 ± 38 < 0.001 – – –
SAPS II 53 ± 22 50 ± 18 46 ± 18 62 ± 23 < 0.001 46 ± 17 58 ± 19 < 0.001
Vasopressor use in first 48 h, % 276 (58) 175 (52) 139 (50) 137 (70) < 0.001 112 (47) 63 (64) 0.01
Mechanical ventilation, % 275 (58) 205 (61) 107 (38) 168 (100) < 0.001 106 (43) 99 (100) < 0.001
ARDS, % 195 (41) 99 (29) – – – – – –
 Mild ARDS, defined as PF or 
SF > 200–300, %
43 (22) 32 (32) – – – – – –
 Moderate ARDS, defined as PF 
or SF 100–200, %
76 (39) 42 (42) – – – – – –
 Severe ARDS, defined as PF or 
SF < 100, %
76 (39) 25 (25) – – – – – –
Hospital LOS 8 (5, 13) 9 (6, 15) 7 (5, 11) 9 (5, 16) 0.004 9 (6, 13) 12 (7, 20) 0.001
Hospital  LOS‡ 8 (5, 13) 10 (7,17) 7 (5, 11) 10 (7, 19) < 0.001 9 (6, 14) 15 (10, 23) < 0.001
ICU LOS 4 (3, 7) 5 (3, 9) 4 (3, 5) 5 (3, 11) < 0.001 4 (3, 6) 8 (5, 13) < 0.001
ICU  LOS‡ 4 (3, 6) 4 (3, 8) 4 (3, 5) 5 (4, 11) < 0.001 4 (3, 5) 9 (5, 13) < 0.001
Ventilator-free days 25 (0, 28) 25 (16, 28) 28 (23, 28) 16 (0, 26) < 0.001 28 (24, 28) 20 (1, 24) < 0.001
ICU mortality, % 105 (22) 46 (14) 36 (13) 69 (35) < 0.001 21 (9) 25 (25) < 0.001
Hospital mortality, % 137 (29) 60 (18) 54 (19) 83 (43) < 0.001 31 (13) 29 (28) < 0.001
Discussion
We determined the association between development 
of ARDS and mortality in two separate ICU cohorts of 
critically ill patients with sepsis. In both cohorts, devel-
opment of ARDS was independently associated with 
higher hospital and ICU mortality, accrual of fewer 
VFDs, and prolonged hospital and ICU LOS. While 
it may not be surprising that severe ARDS portends 
a worse prognosis than moderate or mild disease, the 
varied ability to detect statistically significant mor-
tality differences based on severity of ARDS is, to our 
knowledge, a novel finding. Most recently, Fuchs et al. 
showed no detectable difference in 28-day mortality 
among ventilated patients with or without ARDS, but 
did find that severe ARDS served as a risk factor for 
2-year mortality [17]. Our significant results for in-hos-
pital mortality compared to the results of Fuchs et  al. 
may relate to differences in overall severity of illness 
and our focus on a predominantly medical ICU popula-
tion with sepsis.
Our findings are directly relevant to the growing 
interest in prognostic enrichment for improving criti-
cal care trial design. Prognostic enrichment is defined 
as preferentially targeting enrollment of patients with 
the highest rates of disease-attributable (and, hope-
fully, modifiable) outcomes—in this case, mortality. 
With increasing recognition that current definitions of 
sepsis and ARDS do not identify patients with uniform 
Table 2 Patient characteristics stratified by in‑hospital mortality, EARLI and VALID cohorts
*Data shown as mean ± standard deviation, number (percent), or median (interquartile range) as appropriate
† Modified APACHE scores exclude points related to oxygenation
Clinical variable* Survived (n = 337) Died (n = 137) p value
EARLI patient characteristics
Age, years 64 ± 17 70 ± 15 < 0.001
Male gender, % 176 (53) 79 (57) 0.28
White race, % 174 (52) 65 (47) 0.41
Any limitation on code status at admission, % 55 (16) 33 (24) 0.05
Admitted from nursing facility, % 65 (19) 31 (23) 0.41
Pulmonary sepsis, % 188 (56) 89 (65) 0.07
APACHE II score 24 ± 8 34 ± 9 < 0.001
Modified APACHE II  score† 22 ± 7 32 ± 8 < 0.001
APACHE III score 82 ± 30 129 ± 39 < 0.001
Modified APACHE III  score† 78 ± 28 121 ± 37 < 0.001
SAPS II 45 ± 17 71 ± 20 < 0.001
Vasopressor use in first 48 h, % 172 (51) 104 (76) < 0.001
Mechanically ventilated, % 164 (49) 111 (81) < 0.001
ARDS, % 112 (33) 83 (61) < 0.001
Hospital LOS 8 (5, 13) 7 (3, 13) 0.002
ICU LOS 4 (3, 6) 5 (3, 10) 0.11
Clinical variable* Survived (n = 277) Died (n = 60) p value
VALID patient characteristics
Age, years 55 ± 16 58 ± 16 0.23
Male gender, % 138 (50) 31 (52) 0.80
White race, % 213 (77) 54 (90) 0.02
Pulmonary sepsis, % 134 (48) 38 (63) 0.04
APACHE II score 26 ± 8 32 ± 8 < 0.001
Modified APACHE II  score† 24 ± 8 30 ± 8 < 0.001
SAPS II 47 ± 17 62 ± 19 < 0.001
Vasopressor use in first 48 h, % 133 (48) 42 (70) 0.002
Mechanically ventilated, % 152 (55) 53 (88) < 0.001
ARDS, % 70 (25) 29 (48) 0.001
Hospital LOS 10 (7, 17) 6.5 (4, 10) < 0.001
ICU LOS 4 (3, 8) 6 (4, 9.5) 0.01
and distinct disease processes, and that this hetero-
geneity may be confounding clinical trials, prognostic 
enrichment may offer one reasonable approach [30]. 
While targeting patients with more severe ARDS has 
had some success [6, 31], this study provides the first 
empiric evidence to support such a strategy. Our find-
ings suggest that prognostic enrichment focusing on 
patients with severe ARDS, either as defined by the 
Berlin definition of P/F < 100, or perhaps by P/F < 120, 
as suggested by our data-driven comparison of mortal-
ity risk, may identify individuals most likely to die from 
factors related specifically to ARDS, and therefore may 
provide a population in which we are better able to 
identify beneficial treatments. This finding is consistent 
with a prior autopsy study which reported that patients 
with severe ARDS were more likely to experience 
refractory hypoxemia prior to death and have diffuse 
alveolar damage than patients with mild or moderate 
disease who were more likely to die of refractory shock 
[32].
We also estimated  AFARDS and population  AFARDS and 
found similar results in both cohorts. Attributable frac-
tion of mortality is the proportion of deaths that can be 
statistically attributed to an underlying cause, in this 
case, ARDS [28]. Population attributable fraction of 
mortality is the proportion of deaths within a cohort of 
patients, all of whom are at risk of the underlying cause 
in question: In this case, the proportion of deaths due to 
ARDS among all patients with sepsis. The  AFARDS was 
27% in EARLI and 37% in VALID. The population  AFARDS 
was 16% in EARLI and 18% in VALID. It is helpful to put 
these results in the context of other studies estimating 
attributable mortality of important critical care diseases. 
The attributable fraction of mortality from sepsis was 
recently estimated at 15% [33]. The population attribut-
able fraction of mortality from ICU-acquired infections 
and ICU delirium has been estimated at 11% and 7%, 
respectively [29, 34]. While ARDS may confer mortality 
fractions notably higher than these other important ICU 
conditions, any absolute changes in mortality by fully 
treating or preventing ARDS would still be relatively low. 
As recently illustrated by Shankar-Hari et al., these data 
have major implications for considering the size of clini-
cal trials necessary to detect such changes [33].
This study has several strengths. First, it includes two 
large and diverse prospective cohorts of critically ill 
patients from distinct centers. The similarity of the asso-
ciation between ARDS and in-hospital mortality in these 
very different populations strengthens the validity of our 
findings and suggests generalizability. Second, we found 
relatively consistent results within each cohort when 
adjusting for up to three distinct severity of illness met-
rics. Third, in developing adjusted models, we searched 
methodically for possible confounders and did not find 
other contributory variables. Fourth, all patients were 
meticulously phenotyped for both sepsis and ARDS. 
Finally, in contrast to most studies assessing ARDS and 
attributable mortality, this study expands the populations 
Table 3 Association of ARDS with mortality in unadjusted and adjusted models, EARLI and VALID cohorts
Modified APACHE scores exclude points related to oxygenation
*In addition to severity of illness variable listed in the table, adjusted models include age, limitation on code status at admission, and being admitted from a nursing 
home
† In addition to severity of illness variable listed in the table, adjusted models include age
EARLI logistic regression models (n = 474) OR (95% CI) p value
Unadjusted model of ARDS for in-hospital mortality 3.09 (2.05, 4.66) < 0.001
 Adjusted for modified APACHE II* 1.65 (1.02, 2.67) 0.04
 Adjusted for modified APACHE III* 1.61 (0.98, 2.64) 0.06
 Adjusted for SAPS II* 1.48 (0.9, 2.44) 0.12
Unadjusted model of ARDS for ICU mortality 3.70 (2.34, 5.84) < 0.001
 Adjusted for modified APACHE II* 2.05 (1.23, 3.44) 0.01
 Adjusted for modified APACHE III* 2.03 (1.2, 3.45) 0.01
 Adjusted for SAPS II* 1.85 (1.1, 3.13) 0.02
VALID logistic regression models (n = 337) OR (95% CI) p
Unadjusted model of ARDS for in-hospital mortality 2.77 (1.56, 4.91) 0.001
 Adjusted for modified APACHE  II† 2.12 (1.16, 3.92) 0.02
 Adjusted for SAPS  II† 1.79 (0.95, 3.36) 0.07
Unadjusted model of ARDS for ICU mortality 3.49 (1.85, 6.6) < 0.001
 Adjusted for modified APACHE  II† 2.67 (1.35, 5.27) 0.01
 Adjusted for SAPS  II† 2.14 (1.06, 4.33) 0.03
to include both medical and surgical patients, thereby 
increasing generalizability of results beyond previously 
published studies.
This study has limitations. First, there were some 
discrepancies in specific data collected in each cohort. 
Most notably, we did not have information on code sta-
tus or admission from a nursing home in the VALID 
population. However, incorporation of these variables 
did not significantly affect any of the EARLI mod-
els. In addition, we were unable to generate APACHE 
III scores from the VALID data. To better align the 
cohorts, we chose to utilize APACHE II for our primary 
analyses. While we adjusted for multiple confounders, 
the possibility of residual confounding remains. Spe-
cifically, we did not control for measures of other acute 
organ failures beyond what is captured in APACHE and 
SAPS scores. As depicted in our DAG, we hypothesize 
that other acute organ failures may lie on the indirect 
causal path between ARDS and death, and so were not 
included in our models. However, if the association 
between ARDS and mortality is driven predominantly 
by other organ failures (such as renal or hepatic) that 
develop later in a patient’s ICU stay, or those variables 
are instead predominantly confounders, our analysis 
may not precisely capture that relationship. This caveat 
is important because some prior studies have identified 
increased mortality in ARDS with other organ failures 
or comorbidities [35, 36]. Our study does not explain 
the cause of the observed higher mortality in patients 
with severe ARDS, but future studies focusing on severe 
ARDS should explore this question. Because we began 
enrollment and data collection for both cohorts before 
the advent of Sepsis 3, our coding for sepsis reflects the 
prior definition. However, as we enrolled critically ill 
Fig. 2 Odds ratios with 95% confidence intervals for in-hospital mortality stratified by severity of ARDS. In addition to severity of illness vari-
ables listed in the table, adjusted models for EARLI include age, limitation on code status at admission, and being admitted from a nursing home. 
Adjusted models for VALID include age
patients, it is unlikely that our patients would not fulfill 
the more recent criteria for sepsis [37]. Finally, as our 
study focused on patients with sepsis, the most com-
mon ARDS risk factor, findings may not be generaliz-
able to patients with other risk factors for ARDS.
This study provides important new evidence about 
ARDS-attributable mortality in patients with sepsis and 
quantifies the  AFARDS. In two separate cohorts of ICU 
patients with sepsis, ARDS is independently associ-
ated with hospital and ICU mortality as well as VFDs, 
ICU LOS, and hospital LOS. Importantly, patients with 
the most severe ARDS primarily drove the relationship 
between ARDS and mortality. These findings suggest 
that to successfully identify novel therapeutics or changes 
in practice that may impact mortality, clinical trials for 
ARDS will require significantly larger study populations 
or should focus primarily on patients with severe ARDS.
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